Insider Trading June 12, 2026 06:58 PM

Heartflow CEO Executes $643K Stock Sale Under Pre-Arranged Trading Plan

John Farquhar's divestment occurs as the medical technology firm reports strong Q1 revenue growth and maintains analyst confidence despite valuation concerns.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
HTFL

Heartflow Inc. CEO John C.M. Farquhar sold 22,562 shares of the company's common stock on June 10, 2026, generating proceeds of $643,017 at a price of $28.50 per share. The transaction was carried out under a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Farquhar retains direct ownership of 496,835 shares. The stock has since appreciated to $33.18, reflecting an 18% gain from the sale price and matching its weekly return. According to InvestingPro analysis, HeartFlow's shares appear overvalued relative to fair value estimates, placing the company among the most overvalued equities. In recent financial disclosures, HeartFlow reported first-quarter 2026 earnings that exceeded expectations, with an EPS of -$0.16 against a forecast of -$0.22. Revenue surged 41% year-over-year to $52.6 million, driven by strong global case volume growth. Piper Sandler reiterated its Overweight rating on the stock, maintaining a $38.00 price target and noting that strategic pricing concessions in the FFR-CT business successfully increased volume.

Heartflow CEO Executes $643K Stock Sale Under Pre-Arranged Trading Plan
HTFL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Heartflow CEO John Farquhar sold 22,562 shares at $28.50 per share on June 10, 2026, under a Rule 10b5-1 plan adopted in September 2025, retaining 496,835 shares post-transaction.
  • The company reported Q1 2026 results that beat expectations, with EPS of -$0.16 versus -$0.22 forecast, and revenue surged 41% to $52.6 million driven by global case volume growth.
  • HeartFlow shares have appreciated 18% to $33.18 since the sale, though InvestingPro analysis indicates the stock is overvalued relative to fair value estimates.

Heartflow Inc. (NASDAQ: HTFL) Chief Executive Officer John C.M. Farquhar completed a significant divestment transaction on June 10, 2026, selling 22,562 shares of the company's common stock. The transaction was executed at a price of $28.50 per share, resulting in total proceeds of $643,017. This sale was carried out under the framework of a Rule 10b5-1 trading plan, which Farquhar initially adopted on September 12, 2025. Following the completion of this transaction, Farquhar continues to hold a direct position of 496,835 shares in Heartflow common stock.

Market data indicates that Heartflow's stock price has moved higher since the execution of the sale. The shares have climbed to $33.18, representing an 18% gain from the $28.50 sale price. This upward movement aligns with the stock posting a 18% return over the past week alone. According to analysis from InvestingPro, the current valuation of HeartFlow appears overvalued relative to its Fair Value estimate. This assessment places the company among the list of the most overvalued equities. Investors seeking detailed insights can access a comprehensive Pro Research Report on HTFL, which is available for this equity and over 1,400 other US equities.

Financial performance metrics released by HeartFlow provide context for the recent market activity. The company reported its first-quarter 2026 earnings, which surpassed analyst expectations. The reported earnings per share stood at -$0.16, outperforming the forecasted figure of -$0.22. Revenue also demonstrated substantial growth, reaching $52.6 million. This figure marks a 41% increase from the previous year, a surge attributed to strong global case volume growth.

Analyst sentiment remains constructive despite the CEO's stock sale. Piper Sandler reiterated its Overweight rating on HeartFlow, maintaining a price target of $38.00. The firm noted that HeartFlow's strategic pricing concessions in the FFR-CT business were intentional measures. These concessions have successfully driven more volume, highlighting the company's strategic moves and financial performance during this period.

Risks

  • InvestingPro analysis suggests HeartFlow's stock is overvalued relative to its Fair Value estimate, positioning it among the most overvalued companies, which may indicate valuation risk for investors.
  • The CEO's substantial stock sale, while executed under a pre-arranged trading plan, may signal internal profit-taking or liquidity management, potentially impacting market sentiment in the medical technology sector.

More from Insider Trading

CoreWeave Executive Brian Venturo Disposes of $7.45 Million in Class A Shares Amid Strategic Debt Issuance Jun 12, 2026 Dorian LPG Director Christina Tan Disposes of $251,608 in Company Stock Jun 12, 2026 Silver Lake Affiliates and Dell Director Egon Durban Execute $18.5 Million Stock Sale Jun 12, 2026 Microsoft Executive Takeshi Numoto Executes $1.81 Million Stock Sale Jun 12, 2026 Slide Insurance CRO Liquidates $234,712 in Stock Under Pre-Arranged Plan Jun 12, 2026